Long-acting risperidone is a suspension administered by intramuscular injection in the upper-outer gluteal area. It consists of risperidone impregnated in microspheres composed of a biodegradable ...

Parsippany, New Jersey Thursday, February 27, 2025, 13:00 Hrs [IST] ...

Long-acting risperidone injection was released for marketing for the treatment of schizophrenia in the United States in October 2003. The drug was available in 45 countries as of December 2003.

Proof of Rovi’s commitment to a sustainable business model is the recognition obtained by the company through the evaluation by Sustainalytics. In December 2024, Rovi obtained the fifth position in ...

The application leverages existing clinical data for Uzedy along with prior FDA findings on the safety of Udezy in patients ...

UZEDY is currently approved for use every one or two months as a subcutaneous long-acting injectable (LAI) for the treatment ...

TV46000-CNS-30072 (the RISE Study – The Risperidone Subcutaneous Extended-Release Study) and TV46000-CNS-30078 (the SHINE Study – Safety in Humans of TV-46000 sc INjection Evaluation).

Uzedy (risperidone), a long-acting subcutaneous atypical antipsychotic injection for the treatment of schizophrenia, generated sales of $43 million in the fourth quarter compared with $9 million ...

Things were looking good for the injectable, subcutaneous formulation of the decades old generic antipsychotic risperidone ... that form a depot after injection that degrades over time, slowly ...